Cargando…
Cardiopulmonary bypass and recombinant plasminogen activator for treatment of experimental fatal pulmonary embolism
Autores principales: | Kjærgaard, B, Risom, M, Kristensen, S Risom, Tonnesen, E, Larsson, A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4095417/ http://dx.doi.org/10.1186/cc5524 |
Ejemplares similares
-
Role of plasminogen activator inhibitor-1 polymorphism on the development of vasoplegic syndrome associated with cardiopulmonary bypass
por: Jimenez, J, et al.
Publicado: (2007) -
Tranexamic acid effects on postoperative bleeding in cardiopulmonary bypass surgery according to the plasminogen activator inhibitor-1 polymorphism
por: Brouard, M, et al.
Publicado: (2008) -
Putative Biomarkers for Acute Pulmonary Embolism in Exhaled Breath Condensate
por: Gade, Inger Lise, et al.
Publicado: (2021) -
Influence of amiodarone treatment on inflammation during cardiopulmonary bypass
por: Delle Karth, G, et al.
Publicado: (2005) -
Fibrinolysis during cardiopulmonary bypass detected with thromboelastography
por: Hájek, R, et al.
Publicado: (2007)